Eliem Therapeutics (NASDAQ:ELYM) vs. Sernova (OTCMKTS:SEOVF) Head-To-Head Comparison

Profitability

This table compares Eliem Therapeutics and Sernova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Sernova	N/A	N/A	-283.67%

Volatility and Risk

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Comparatively, Sernova has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Institutional and Insider Ownership

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Eliem Therapeutics and Sernova”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-2.43
Sernova	N/A	N/A	-$23.65 million	($0.05)	-3.00

Sernova is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.